Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage. 2016

Roberto Arriga, and Sara Caratelli, and Andrea Coppola, and Giulio Cesare Spagnoli, and Adriano Venditti, and Sergio Amadori, and Giulia Lanzilli, and Davide Lauro, and Patrizia Palomba, and Tommaso Sconocchia, and Maria Ilaria Del Principe, and Luca Maurillo, and Francesco Buccisano, and Barbara Capuani, and Soldano Ferrone, and Giuseppe Sconocchia
Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.

Acute myeloid leukemia (AML) cells induce, in vitro, NK cell abnormalities (NKCAs) including apoptosis and activating receptor down-regulation. The potential negative impact of AML cells on the therapeutic efficacy of NK cell-based strategies prompted us to analyze the mechanisms underlying NKCAs and to develop approaches to protect NK cells from NKCAs. NKCA induction by the AML leukemia cells target a subpopulation of peripheral blood NK cells and is interleukin-2 independent but is abrogated by a long-term culture of NK (LTNK) cells at 37°C. LTNK cells displayed a significantly enhanced ability to damage AML cells in vitro and inhibited the subcutaneous growth of ML-2 cells grafted into CB17 SCID mice. Actinomycin D restored the susceptibility of LTNK cells to NKCAs while TAPI-0, a functional analog of the tissue inhibitor of metalloproteinase (TIMP) 3, inhibits ML-2 cell-induced NKCAs suggesting that the generation of NK cell resistance to NKCAs involves RNA transcription and metalloproteinase (MPP) inactivation. This conclusion is supported by the reduced susceptibility to AML cell-induced NKCAs of LTNK cells in which TIMP3 gene and protein are over-expressed. This information may contribute to the rational design of targeted strategies to enhance the efficacy of NK cell-based-immunotherapy of AML with haploidentical NK cells.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute

Related Publications

Roberto Arriga, and Sara Caratelli, and Andrea Coppola, and Giulio Cesare Spagnoli, and Adriano Venditti, and Sergio Amadori, and Giulia Lanzilli, and Davide Lauro, and Patrizia Palomba, and Tommaso Sconocchia, and Maria Ilaria Del Principe, and Luca Maurillo, and Francesco Buccisano, and Barbara Capuani, and Soldano Ferrone, and Giuseppe Sconocchia
January 1990, International journal of immunopharmacology,
Roberto Arriga, and Sara Caratelli, and Andrea Coppola, and Giulio Cesare Spagnoli, and Adriano Venditti, and Sergio Amadori, and Giulia Lanzilli, and Davide Lauro, and Patrizia Palomba, and Tommaso Sconocchia, and Maria Ilaria Del Principe, and Luca Maurillo, and Francesco Buccisano, and Barbara Capuani, and Soldano Ferrone, and Giuseppe Sconocchia
November 2017, Oncotarget,
Roberto Arriga, and Sara Caratelli, and Andrea Coppola, and Giulio Cesare Spagnoli, and Adriano Venditti, and Sergio Amadori, and Giulia Lanzilli, and Davide Lauro, and Patrizia Palomba, and Tommaso Sconocchia, and Maria Ilaria Del Principe, and Luca Maurillo, and Francesco Buccisano, and Barbara Capuani, and Soldano Ferrone, and Giuseppe Sconocchia
June 1994, Bratislavske lekarske listy,
Roberto Arriga, and Sara Caratelli, and Andrea Coppola, and Giulio Cesare Spagnoli, and Adriano Venditti, and Sergio Amadori, and Giulia Lanzilli, and Davide Lauro, and Patrizia Palomba, and Tommaso Sconocchia, and Maria Ilaria Del Principe, and Luca Maurillo, and Francesco Buccisano, and Barbara Capuani, and Soldano Ferrone, and Giuseppe Sconocchia
December 2008, Ultrasonics,
Roberto Arriga, and Sara Caratelli, and Andrea Coppola, and Giulio Cesare Spagnoli, and Adriano Venditti, and Sergio Amadori, and Giulia Lanzilli, and Davide Lauro, and Patrizia Palomba, and Tommaso Sconocchia, and Maria Ilaria Del Principe, and Luca Maurillo, and Francesco Buccisano, and Barbara Capuani, and Soldano Ferrone, and Giuseppe Sconocchia
March 2022, Journal for immunotherapy of cancer,
Roberto Arriga, and Sara Caratelli, and Andrea Coppola, and Giulio Cesare Spagnoli, and Adriano Venditti, and Sergio Amadori, and Giulia Lanzilli, and Davide Lauro, and Patrizia Palomba, and Tommaso Sconocchia, and Maria Ilaria Del Principe, and Luca Maurillo, and Francesco Buccisano, and Barbara Capuani, and Soldano Ferrone, and Giuseppe Sconocchia
February 2008, Molecular immunology,
Roberto Arriga, and Sara Caratelli, and Andrea Coppola, and Giulio Cesare Spagnoli, and Adriano Venditti, and Sergio Amadori, and Giulia Lanzilli, and Davide Lauro, and Patrizia Palomba, and Tommaso Sconocchia, and Maria Ilaria Del Principe, and Luca Maurillo, and Francesco Buccisano, and Barbara Capuani, and Soldano Ferrone, and Giuseppe Sconocchia
October 2017, Oncotarget,
Roberto Arriga, and Sara Caratelli, and Andrea Coppola, and Giulio Cesare Spagnoli, and Adriano Venditti, and Sergio Amadori, and Giulia Lanzilli, and Davide Lauro, and Patrizia Palomba, and Tommaso Sconocchia, and Maria Ilaria Del Principe, and Luca Maurillo, and Francesco Buccisano, and Barbara Capuani, and Soldano Ferrone, and Giuseppe Sconocchia
January 1989, Xenobiotica; the fate of foreign compounds in biological systems,
Roberto Arriga, and Sara Caratelli, and Andrea Coppola, and Giulio Cesare Spagnoli, and Adriano Venditti, and Sergio Amadori, and Giulia Lanzilli, and Davide Lauro, and Patrizia Palomba, and Tommaso Sconocchia, and Maria Ilaria Del Principe, and Luca Maurillo, and Francesco Buccisano, and Barbara Capuani, and Soldano Ferrone, and Giuseppe Sconocchia
October 2001, Cancer immunology, immunotherapy : CII,
Roberto Arriga, and Sara Caratelli, and Andrea Coppola, and Giulio Cesare Spagnoli, and Adriano Venditti, and Sergio Amadori, and Giulia Lanzilli, and Davide Lauro, and Patrizia Palomba, and Tommaso Sconocchia, and Maria Ilaria Del Principe, and Luca Maurillo, and Francesco Buccisano, and Barbara Capuani, and Soldano Ferrone, and Giuseppe Sconocchia
May 2013, Blood,
Copied contents to your clipboard!